|
1
|
Bianchi B, Ferri A, Ferrari S, et al:
Reconstruction of lateral through and through oro-mandibular
defects following oncological resections. Microsurgery. 30:517–525.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thankappan K, Kuriakose MA, Chatni SS,
Sharan R, Trivedi NP, Vijayaraghavan S, Sharma M and Iyer S:
Lateral arm free flap for oral tongue reconstruction: An analysis
of surgical details, morbidity, and functional and aesthetic
outcome. Ann Plast Surg. 66:261–266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zeno HA, Sternberger SS, Tuminelli FJ,
Billotte M and Kurtz KS: Combination lower lip prosthesis retained
by an intraoral component. J Prosthodont. 22:397–401. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kawase-Koga Y, Mori Y, Saijo H, Hoshi K
and Takato T: Reconstruction of a complex midface defect from
excision of a squamous cell carcinoma, according to regional
aesthetic units. Oral Surg Oral Med Oral Pathol Oral Radiol.
117:e97–e101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chiesa F, Mauri S, Tradati N, Calabrese L,
Giugliano G, Ansarin M, Andrle J, Zurrida S, Orecchia R and Scully
C: Surfing prognostic factors in head and neck cancer at the
millennium. Oral Oncol. 35:590–596. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brinkman BM and Wong DT: Disease mechanism
and biomarkers of oral squamous cell carcinoma. Curr Opin Oncol.
18:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Babu GS, Supriya AN, Kumar Raj NG and
Swetha P: Tumor markers: An overview. J Orofac Sci. 3:87–95.
2012.
|
|
8
|
Sudbø J and Reith A: The evolution of
predictive oncology and molecular-based therapy for oral cancer
prevention. Int J Cancer. 115:339–345. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kujubu DA, Reddy ST, Fletcher BS and
Herschman HR: Expression of the protein product of the
prostaglandin synthase-2/TIS10 gene in mitogen-stimulated Swiss 3T3
cells. J Biol Chem. 268:5425–5430. 1993.PubMed/NCBI
|
|
10
|
Vane J: Towards a better aspirin. Nature.
367:215–216. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shibata M, Kodani I, Osaki M, Araki K,
Adachi H, Ryoke K and Ito H: Cyclo-oxygenase-1 and-2 expression in
human oral mucosa, dysplasias and squamous cell carcinomas and
their pathological significance. Oral Oncol. 41:304–312. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wood ZA, Schröder E, Robin Harris J and
Poole LB: Structure, mechanism and regulation of peroxiredoxins.
Trends Biochem Sci. 28:32–40. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yanagawa T, Ishikawa T, Ishii T, Tabuchi
K, Iwasa S, Bannai S, Omura K, Suzuki H and Yoshida H:
Peroxiredoxin I expression in human thyroid tumors. Cancer Lett.
145:127–132. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kinnula VL, Lehtonen S, Sormunen R,
Kaarteenahob WR, Kang SW, Rhee SG and Soini Y: Overexpression of
peroxiredoxins III, IIIV and VI in malignant mesothelioma. J
Pathol. 196:316–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chang JW, Jeon HB, Lee JH, Yoo JS, Chun
JS, Kim JH and Yoo YJ: Augmented expression of peroxiredoxin I in
lung cancer. Biochem Biophys Res Commun. 289:507–512. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA
and Chae HZ: Overexpression of peroxiredoxin in human breast
cancer. Anticancer Res. 21:2085–2090. 2001.PubMed/NCBI
|
|
17
|
Prosperi MT, Ferbus D, Karczinski I and
Goubin G: A human cDNA corresponding to a gene overexpressed during
cell proliferation encodes a product sharing homology with amoebic
and bacterial proteins. J Biol Chem. 268:11050–11056.
1993.PubMed/NCBI
|
|
18
|
Kang SW, Chae HZ, Seo MS, Kim K, Baines IC
and Rhee SG: Mammalian peroxiredoxin isoforms can reduce hydrogen
peroxide generated in response to growth factors and tumor necrosis
factor-alpha. J Biol Chem. 273:6297–6302. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Klaunig JE, Xu Y, Isenberg JS, Bachowski
S, Kolaja KL, Jiang J, Stevenson DE and Walborg EF Jr: The role of
oxidative stress in chemical carcinogenesis. Environ Health
Perspect. 106:289–295. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fujii J and Ikeda Y: Advances in our
understanding of peroxiredoxin, a multifunctional, mammalian redox
protein. Redox Rep. 7:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ishii T, Yamada M, Sato H, Matsue M,
Taketani S, Nakayama K, Sugita Y and Bannai S: Cloning and
characterization of a 23-kDa stress-induced mouse peritoneal
macrophage protein. J Biol Chem. 268:18633–18636. 1993.PubMed/NCBI
|
|
22
|
Liu M, Lawson G, Delos M, Jamart J, Ide C,
Coche E, Weynand B, Desuter G, Hamoir M, Remacle M and Marbaix E:
Predictive value of the fraction of cancer cells immunolabeled for
proliferating cell nuclear antigen or Ki67 in biopsies of head and
neck carcinomas to identify lymph node metastasis: Comparison with
clinical and radiologic examinations. Head Neck. 25:280–288. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Matsumoto A, Okado A, Fujii T, Fujii J,
Egashira M, Niikawa N and Taniguchi N: Cloning of the peroxiredoxin
gene family in rats and characterization of the fourth member. FEBS
Lett. 443:246–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neumann CA, Krause DS, Carman CV, Das S,
Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH and Van
Etten RA: Essential role for the peroxiredoxin Prdx1 in erythrocyte
antioxidant defence and tumour suppression. Nature. 424:561–565.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Greene FL, Page D, Morrow M, et al: Lip
and oral cavity. AJCC Cancer Staging Manual (6th). (New York).
Springer. 23–32. 2002.
|
|
26
|
Wolff H, Saukkonen K, Anttila S,
Karjalainen A, Vainio H and Ristimäki A: Expression of
cyclooxygenase-2 in human lung carcinoma. Cancer Res. 58:4997–5001.
1998.PubMed/NCBI
|
|
27
|
Shamma A, Yamamoto H, Doki Y, Okami J,
Kondo M, Fujiwara Y, Yano M, Inoue M, Matsuura N, Shiozaki H and
Monden M: Up-regulation of cyclooxygenase-2 in squamous
carcinogenesis of the esophagus. Clin Cancer Res. 6:1229–1238.
2000.PubMed/NCBI
|
|
28
|
Peng JP, Su CY, Chang HC, Chai CY and Hung
WC: Overexpression of cyclo-oxygenase 2 in squamous cell carcinoma
of the hypopharynx. Hum Pathol. 33:100–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Banerjee AG, Gopalakrishnan VK,
Bhattacharya I and Vishwanatha JK: Deregulated cyclooxygenase-2
expression in oral premalignant tissues. Mol Cancer Ther.
1:1265–1271. 2002.PubMed/NCBI
|
|
30
|
Yu HP, Xu SQ, Liu L, Shi LY, Cai XK, Lu
WH, Lu B, Su YH and Li YY: Cyclo-oxygenase-2 expression in squamous
dysplasia and squamous cell carcinoma of the esophagus. Cancer
lett. 198:193–201. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsujii M and DuBois RN: Alterations in
cellular adhesion and apoptosis in epithelial cells overexpressing
prostaglandin endoperoxide synthase 2. Cell. 83:493–501. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhi H, Wang L, Zhang J, Zhou C, Ding F,
Luo A, Wu M, Zhan Q and Liu Z: Significance of COX-2 expression in
human esophageal squamous cell carcinoma. Carcinogenesis.
27:1214–1221. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kase S, Osaki M, Honjo S, Adachi H,
Tsujitani S, Kaibara N and Ito H: Expression of cyclo-oxygenase-2
is correlated with high intratumoral microvessel density and low
apoptotic index in human esophageal squamous cell carcinomas.
Virchows Arch. 442:129–135. 2003.PubMed/NCBI
|
|
34
|
Quan C, Cha EJ, Lee HL, Han KH, Lee KM and
Kim WJ: Enhanced expression of peroxiredoxin I and 6 correlates
with development, recurrence and progression of human bladder
cancer. J Urol. 175:1512–1516. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lehtonen ST, Svensk AM, Soini Y, Pääkkö P,
Hirvikoski P, Kang SW, Säily M and Kinnula VL: Peroxiredoxins, a
novel protein family in lung cancer. Int J Cancer. 111:514–521.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yanagawa T, Iwasa S, Ishii T, Tabuchi K,
Yusa H, Onizawa K, Omura K, Harada H, Suzuki H and Yoshida H:
Peroxiredoxin I expression in oral cancer: A potential new tumor
marker. Cancer Lett. 156:27–35. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wen ST and Van Etten RA: The pag gene
product, a stress-induced protein with antioxidant properties, is
an abl SH3-binding protein and a physiological inhibitor of c-Abl
tyrosine kinase activity. Genes Dev. 11:2456–2467. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Prospéri MT, Ferbus D, Rouillard D and
Goubin G: The pag gene product, a physiological inhibitor of c-abl
tyrosine kinase, is overexpressed in cells entering S phase and by
contact with agents inducing oxidative stress. FEBS Lett.
423:39–44. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yanagawa T, Omura K, Harada H, Ishii T,
Uwayama J, Nakaso K, Iwasa S, Koyama Y, Onizawa K, Yusa H and
Yoshida H: Peroxiredoxin I expression in tongue squamous cell
carcinomas as involved in tumor recurrence. Int J Oral Maxillofac
Surg. 34:915–920. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Richmond A: NF-kappa B chemokine gene
transcription and tumour growth. Nat Rev Immunol. 2:664–674. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Loercher A, Lee TL, Ricker JL, Howard A,
Geoghegen J, Chen Z, Sunwoo JB, Sitcheran R, Chuang EY, Mitchell
JB, et al: Nuclear factor-kappaB is an important modulator of the
altered gene expression profile and malignant phenotype in squamous
cell carcinoma. Cancer Res. 64:6511–6523. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Takada Y, Singh S and Aggarwal BB:
Identification of a p65 peptide that selectively inhibits NF-kappa
B activation induced by various inflammatory stimuli and its role
in down-regulation of NF-kappaB-mediated gene expression and
up-regulation of apoptosis. J Biol Chem. 279:15096–15104. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wolf JS, Chen Z, Dong G, Sunwoo JB,
Bancroft CC, Capo DE, Yeh NT, Mukaida N and Van Waes C: IL
(interleukin)-1alpha promotes nuclear factor-kappaB and
AP-1-induced IL-8 expression, cell survival and proliferation in
head and neck squamous cell carcinomas. Clin Cancer Res.
7:1812–1820. 2001.PubMed/NCBI
|
|
44
|
Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh
NT, Jackson S, Jackson C and Van Waes C: Effects of pharmacologic
antagonists of epidermal growth factor receptor, PI3K and MEK
signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF
expression in human head and neck squamous cell carcinoma lines.
Int J Cancer. 99:538–548. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nakayama H, Ikebe T, Beppu M and Shirasuna
K: High expression levels of nuclear factor kappaB IkappaB kinase
alpha and Akt kinase in squamous cell carcinoma of the oral cavity.
Cancer. 92:3037–3044. 2001. View Article : Google Scholar : PubMed/NCBI
|
